Mitsubishi UFJ Trust & Banking Corp Sells 20,130 Shares of BioNTech SE (NASDAQ:BNTX)

Mitsubishi UFJ Trust & Banking Corp reduced its position in BioNTech SE (NASDAQ:BNTX) by 8.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 216,950 shares of the company’s stock after selling 20,130 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.09% of BioNTech worth $20,014,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. boosted its stake in BioNTech by 0.5% during the third quarter. American Century Companies Inc. now owns 87,356 shares of the company’s stock worth $9,490,000 after acquiring an additional 421 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in BioNTech by 33.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 1,240 shares of the company’s stock worth $131,000 after acquiring an additional 314 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in BioNTech by 27.1% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 6,611 shares of the company’s stock worth $698,000 after acquiring an additional 1,411 shares in the last quarter. Schechter Investment Advisors LLC bought a new position in BioNTech during the fourth quarter worth $203,000. Finally, Fifth Third Bancorp boosted its stake in BioNTech by 3,881.3% during the fourth quarter. Fifth Third Bancorp now owns 16,642 shares of the company’s stock worth $1,756,000 after acquiring an additional 16,224 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BNTX has been the topic of several research analyst reports. Evercore ISI initiated coverage on shares of BioNTech in a research note on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. UBS Group dropped their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and issued a $113.00 price objective on shares of BioNTech in a research note on Wednesday, June 26th. BMO Capital Markets dropped their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 7th. Finally, TD Cowen raised their price objective on shares of BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a research note on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $111.70.

BioNTech Stock Performance

NASDAQ BNTX traded down $0.91 during trading hours on Friday, reaching $85.46. 433,886 shares of the company were exchanged, compared to its average volume of 642,484. BioNTech SE has a 1 year low of $78.02 and a 1 year high of $125.83. The business’s 50 day simple moving average is $90.03 and its 200-day simple moving average is $92.34. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $20.32 billion, a P/E ratio of 170.92 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $203.69 million for the quarter, compared to analysts’ expectations of $589.96 million. On average, equities research analysts expect that BioNTech SE will post -2 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.